<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864317</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-220213</org_study_id>
    <nct_id>NCT01864317</nct_id>
  </id_info>
  <brief_title>Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging</brief_title>
  <official_title>Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular
      pressure (IOP) has been identified as the most important risk factor. However, some patients
      progress despite adequate IOP lowering while some subjects with elevated IOP never develop
      glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal
      range. Therefore, other factors must be involved. In the last years, studies using MRI have
      been performed and evidence has accumulated that also changes in retrobulbar structures are
      present, in particular in the lateral geniculate nucleus and the visual cortex. However,
      these studies were limited by the low spatial resolution of the MRI instruments used.

      The investigators propose to overcome this problem by using an ultrahigh-field Magnetom 7T
      whole-body MR scanner (Siemens Medical, Germany) installed at the MR Centre of Excellence at
      the Medical University of Vienna. This scanner is equipped with a 32-channel head coil and
      the SC72 high-performance gradient system and is thus perfectly suited for structural and
      functional imaging. The aim of the present study is to investigate whether structural and
      functional parameters are altered in patients with primary open angle glaucoma (POAG), normal
      tension glaucoma (NTG), ocular hypertension (OHT) compared to healthy control subjects. The
      exact topographical survey of intracranial structures such as the LGN and the assessment of
      neuronal structures by DTI may allow for the better assessment of therapeutic responses to
      new neuroprotective agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High resolution functional and structural imaging of the visual pathway</measure>
    <time_frame>once on the study day (approximately 1 hour)</time_frame>
    <description>The visual pathway will be imaged with 7-Tesla MRI. The images will be compared between the study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fiber thickness</measure>
    <time_frame>once on the study day (approximately 10 minutes)</time_frame>
    <description>Parameters obtained from GDX and OCT measurements will be compared between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field test</measure>
    <time_frame>once on the study day (approximately 20 minutes)</time_frame>
    <description>Parameters from the Humphrey visual field test will be used for classification of severity of glaucoma or to prove that subjects are healthy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>once on the study day (1 minute)</time_frame>
    <description>Goldmann applanation tonometry will be used for measurement of intraocular pressure.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with primary open angle glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with normal tension glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with ocular hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7-Tesla MRI</intervention_name>
    <description>High resolution functional and structural imaging of the visual pathway</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Measurement of retinal nerve fiber thickness</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heidelberg Retina Tomography</intervention_name>
    <description>Measurement of retinal nerve fiber thickness</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Scanning Laser Polarimetry</intervention_name>
    <description>Measurement of retinal nerve fiber thickness</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Humphrey Perimetry</intervention_name>
    <description>Visual Field Testing</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Applanation Tonometry</intervention_name>
    <description>Measurement of Intraocular Pressure</description>
    <arm_group_label>Primary Open Angle Glaucoma</arm_group_label>
    <arm_group_label>Normal Tension Glaucoma</arm_group_label>
    <arm_group_label>Ocular Hypertension</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy controls

          -  Men and women aged over 18 years

          -  Normal findings in the medical history unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings

        Patients with ocular hypertension

          -  Men and women aged over 18 years

          -  Normal findings in the medical history unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings except presence of ocular hypertension (defined as
             untreated IOP ≥ 21 mmHg on at least three measurements in the medical history, no
             signs of glaucomatous damage in the optic disc or the glaucoma hemifield test)

        Patients with primary open angle glaucoma

          -  Men and women aged over 18 years

          -  Normal findings in the medical history unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Diagnosis of manifest primary open angle glaucoma (defined as pathological optic disc
             appearance, glaucoma hemifield test outside normal limits and untreated IOP &gt; 20 mmHg
             on at least three measurements in the medical history)

          -  Mean Deviation in the visual field test ≥ 10dB

        Patients with normal-tension glaucoma

          -  Men and women aged over 18 years

          -  Normal findings in the medical history unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Diagnosis of normal-tension glaucoma (defined as pathological optic disc appearance,
             glaucoma hemifield test outside normal limits and untreated IOP ≤ 20 mmHg on at least
             three measurements in the medical history)

          -  Mean Deviation in the visual field test ≥ 10dB

        Exclusion Criteria:

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Presence or history of a severe medical condition as judged by the clinical
             investigator

          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks
             preceding the study

          -  Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure

          -  Intraocular surgery within the last 6 months

          -  Ocular inflammation or infection within the last 3 months

          -  Pregnancy, planned pregnancy or lactating

          -  Any metallic, electric, electronic or magnetic device or object not removable except
             dental fillings

          -  Claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Bata, MD, MSc</last_name>
    <phone>+43140400</phone>
    <phone_ext>29880</phone_ext>
    <email>ahmed.bata@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>2981</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>7-Tesla Magnetic Resonance Imaging</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Retinal Nerve Fiber Thickness</keyword>
  <keyword>Visual Field Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

